Meyka Pro banner
Qyuns Therapeutics Co., Ltd.

Qyuns Therapeutics Co., Ltd. (2509.HK) Stock Competitors & Peer Comparison

See (2509.HK) competitors and their performances in Stock Market.

2509.HKHKSE
HealthcareBiotechnology
HK$16.24
HK$0.21(1.28%)
Hong Kong Market is Open · 14:25

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
2509.HKHK$16.02+0.75%3.6B9.75HK$1.64N/A
4332.HKHK$1,850.00+0.00%998.5B45.81HK$40.38N/A
6160.HKHK$191.90+0.58%250.3B83.91HK$2.21N/A
1801.HKHK$92.55-1.75%154.9B163.57HK$0.54N/A
2269.HKHK$38.46-2.19%153.2B28.94HK$1.28N/A
6990.HKHK$520.50-0.38%113.4B-241.15-HK$2.02N/A
9926.HKHK$93.60-8.06%81.3B-65.86-HK$1.34N/A
3347.HKHK$38.48-1.94%44.5B37.56HK$0.98+0.39%
6821.HKHK$120.50-6.37%42.3B38.43HK$3.05+1.28%
1530.HKHK$16.87-5.81%40.4B4.21HK$3.84+1.55%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

2509.HK vs 4332.HK Comparison July 2026

2509.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2509.HK stands at 3.6B. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 2509.HK is priced at HK$16.02, while 4332.HK trades at HK$1,850.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2509.HK currently has a P/E ratio of 9.75, whereas 4332.HK's P/E ratio is 45.81. In terms of profitability, 2509.HK's ROE is +0.68%, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 2509.HK is more volatile compared to 4332.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2509.HK.Check 4332.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions